Premium
Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia
Author(s) -
Bowcock S. J.,
Galton D. A. G.,
Goldman J. M.
Publication year - 1989
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1989.tb01477.x
Subject(s) - pancytopenia , medicine , bone marrow aplasia , aplasia , busulfan , chronic myeloid leukaemia , bone marrow , stem cell , myeloid leukemia , myeloid , immunology , chemotherapy , cyclophosphamide , biology , genetics
A 31‐year‐old woman with Philadelphia chromosome‐positive chronic myeloid leukaemia (CML) was treated intermittently with high‐dose busulphan over a 6‐yr period (total dose 1320 mg). 3 yr later (after receiving no further cytotoxic drugs) she developed pancytopenia and marrow aplasia of relatively abrupt onset. Transfusion of reconstituted blood‐derived stem cells (collected 7 yr previously) re‐established chronic phase CML. These events are more consistent with ‘stem cell exhaustion’ than with an acquired marrow microenvironmental defect occurring in the course of CML. The contribution of busulphan is uncertain.